Compare TU & VTRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TU | VTRS |
|---|---|---|
| Founded | 1993 | 1961 |
| Country | Canada | United States |
| Employees | N/A | 30000 |
| Industry | Telecommunications Equipment | Medicinal Chemicals and Botanical Products |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.3B | 18.7B |
| IPO Year | 2000 | 2019 |
| Metric | TU | VTRS |
|---|---|---|
| Price | $9.83 | $16.70 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 4 | 4 |
| Target Price | ★ $17.63 | $13.50 |
| AVG Volume (30 Days) | 8.5M | ★ 9.5M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | ★ 9.96% | 3.21% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.05 |
| Revenue | N/A | ★ $14,299,900,000.00 |
| Revenue This Year | $4.94 | $4.41 |
| Revenue Next Year | $2.76 | $1.96 |
| P/E Ratio | ★ $25.82 | $330.80 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.20 | $9.43 |
| 52 Week High | $16.65 | $18.39 |
| Indicator | TU | VTRS |
|---|---|---|
| Relative Strength Index (RSI) | 43.41 | 50.66 |
| Support Level | $9.20 | $15.84 |
| Resistance Level | $10.70 | $17.17 |
| Average True Range (ATR) | 0.21 | 0.50 |
| MACD | 0.06 | -0.01 |
| Stochastic Oscillator | 52.21 | 29.48 |
Telus is one of the Big Three wireless service providers in Canada, with over 10 million mobile phone subscribers nationwide constituting almost 30% of the total market. It is the incumbent local exchange carrier in the western Canadian provinces of British Columbia and Alberta, where it provides internet, television, and landline phone services. It also has a small wireline presence in eastern Quebec. Mostly because of recent acquisitions, more than 20% of Telus' sales now come from nontelecom businesses, most notably in the international business services, health, security, and agriculture industries. The firm has a 55% economic stake in Telus International.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.